Breast cancer and hormone-replacement therapy: the Million Women Study.

By M. Garton. The Lancet, 2003

1,540 citations recorded by the source corpus.

Subfields: Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/40c85cf4cf8c1ab030b87396083bd3844ffd1f74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. humAn cArcinogens
2. Iarc Monographs
3. P. Gøtzsche
4. Francoise Clavel-Chapelon
5. F. Bray
6. Douglas G. Altman
7. D. M. Parkin
8. Charles Poole

In Oncology

1. F. Bray
2. D. M. Parkin
3. P. Gøtzsche
4. Francoise Clavel-Chapelon
5. Douglas G. Altman
6. Charles Poole
7. G. Reeves
8. C. Mulrow

Citations in the corpus

• Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007, positive): “Example ‘‘10 years’ use of HRT [hormone replacement therapy] is estimated to result in five (95% CI 3–7) additional breast cancers per 1000 users of oestrogen-only preparations and 19 (15–23) additional cancers per 1000 users of oestrogenprogestagen combinations’’ [163].”
• Risk Factors and Preventions of Breast Cancer (2017, background): “66 between current users of HRT and those who never used it [74].”
• Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy (2011, positive): “We had previously reported on the association between use of hormone therapy and breast cancer risk in this cohort (7).”
• The changing global patterns of female breast cancer incidence and mortality (2004, background): “The long-standing hypothesis that breastfeeding of longer duration is protective [57] has been affirmed again recently [58].”
• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “Of the ten cohort studies reported since 1999, four found increased risk of breast cancer from ever use of estrogen alone (Colditz & Rosner, 2000; Beral et al., 2003; Bakken et al., 2004; Ewertz et al., 2005).”
• Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007, neutral): “Example “10 years' use of HRT [hormone-replacement therapy] is estimated to result in five (95% CI 3e7) additional breast cancers per 1000 users of oestrogen-only preparations and 19 (15e23) additional cancers per 1000 users of oestrogenprogestagen combinations” [163].”
• Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study (2007, background): “that the excess in risk associated with HRT use diminishes after treatment stop [4, 7, 10].”
• The pros and cons of phytoestrogens (2010, neutral): “Although pharmaceutical hormone replacement therapy is effective in most cases, this option has fallen out of favor because of fears that its use increases the risk of developing breast cancer risk [238,27].”